Investigational drug · Phase 3
GNR-055
Also called: GNR-055 1.0-2.0
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mucopolysaccharidosis Type II, Metabolic Diseases.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "GNR-055"
First trial start
2021
Nov 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GNR-055", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mucopolysaccharidosis Type II
- Metabolic Diseases
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "GNR-055" as an intervention, largest first.
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type IIPivotal-lookingActive, not recruiting
AO GENERIUMIndustry
NCT05208281 · 32 participants (planned) · Start Nov 30, 2021 · Primary completion Dec 20, 2027
Drug: GNR-055 1.0-2.0-3.0 mg/kg; GNR-055 2.0 mg/kg and 1 more · For: Mucopolysaccharidosis Type II; Metabolic Diseases
Sites: Moscow, Russia; Saint Petersburg, Russia; Simferopol, Russia · 5 sites in all
- A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy VolunteersCompleted
AO GENERIUMIndustry
NCT04539340 · 20 participants · Start Feb 28, 2020 · Primary completion Sep 8, 2020
Drug: GNR-055 · For: Mucopolysaccharidosis Type II; Metabolic Diseases
Sites: Moscow, Russia
AO GENERIUMIndustry
NCT06475404 · 18 participants · Start Apr 6, 2023 · Primary completion Sep 20, 2023
Drug: verenafusp alfa 6 mg/kg; verenafusp alfa 9 mg/kg and 1 more · For: Mucopolysaccharidosis Type II; Metabolic Diseases
Sites: Moscow, Russia
Newest research
PubMed records naming it or its code names, newest first.
- [Safety, tolerability, and pharmacokinetics of verenafusp alfa in healthy volunteers: results of an open-label multicohort phase I study].
Smolyarchuk EA, Sologova SS, Bushmanova AV, et al. · Ter Arkh 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.